Troubled startup Theranos has voided two years' worth of blood-test results from its flagship Edison machines, reports The Wall Street Journal.Those machines are Theranos' main claim to fame.CEO Elizabeth Holmes rose to prominence on the huge promise that, with Edison, Theranos can test for blood-borne diseases with only a pinprick of blood from a fingertip.But amid larger concerns over the accuracy and viability of the Edison technology, Theranos has told federal regulators that it's thrown out all results from 2014 and 2015.That includes tests that Theranos did with Edison, as well as the ones it performed with traditional lab equipment, according to The Journal's report.That means that anybody who got a Theranos blood test during that period may have gotten wrong results.The Journal report indicates that physicians in Phoenix have gotten corrected results from Theranos in recent weeks.In fact, one patient went to the emergency room in 2014 based on a Theranos blood-test result, says the report — a result that's now been amended.The move to throw the test results out is a sign that Theranos is trying to show government agencies that it can regulate its own shortcomings."We've taken comprehensive corrective measures to address the issues CMS raised in their observations.As these matters are currently under review, we have no further comment at this time," the company said, referring to the US Centers for Medicare and Medicaid Services.NOW WATCH: How NASA s groundbreaking work on human blood can predict your reaction to certain drugsLoading video...
The wearable also has electrocardiogram EKG sensors, which combined with the lactate results, extends the patch s usefulness out of sports tracking, and into medicine.The two data sets could help- physicians identify, prevent, or manage cardiovascular disease.Various prototypes have been produced, where scientists worked on finding the correct distance between the sensors to ensure they didn t interfere with each other.Our bodies produce lactate when muscles require lots of energy very quickly, and is therefore helpful to measure how we re coping when exercising very hard, and is also used when people are being kept alive on life support machines, where it s an important metric for improving chances of recovery.The team has tested it on three people so far, and has found the EKG is equally as accurate as ones found on fitness bands already.The Chem-Phys patch is not about to become a product we can buy just yet, but the team says it has already had interest in the device from Olympians, which should help push the product forward.
The round, led by leading healthcare provider InterMountain Healthcare, will be used to accelerate the development of Zebra s imaging analytics engine and create neural networks that will use Zebra s vast imaging dataset to assist radiologists with automated diagnostic algorithms.KIBBUTZ SHEFAYIM, Israel– BUSINESS WIRE –May 25, 2016– Zebra Medical Vision is announcing an additional financing round of $12 million led by InterMountain Healthcare, with the participation of existing investors.Zebra Medical Vision was founded in 2014 with the vision of teaching computers to automatically read and diagnose medical imaging data.The company s analytics engine helps physicians and healthcare providers analyze millions of imaging records, in an effort to close the diagnostic gap created by a billion people worldwide joining the middle class in the coming decade, who will require diagnostic services.These algorithms, developed using Zebra s platform, can be applied to provide health and risk management insights to patients and providers.We are privileged that one of the top healthcare systems in the U.S. has placed such confidence in our team and our platform, added Elad Benjamin, Zebra s CEO, In an environment where computing power and machine learning frameworks are becoming a commodity, the ability to quickly and efficiently curate large quantities of data from a world class integrated healthcare provider can make the difference between simplistic tools and insights that can truly add clinical value and positively impact patient care.
This one s a bit complicated, with organizations releasing sniping press releases and op-eds trying to discredit one another over mammogram screening guidelines.In what turned out to be a highly contentious move, earlier this year the US Preventive Services Task Force UPSTF issued a new set of recommendations.For those with a family history of breast, ovarian, tubal, or peritoneal cancer, the USPSTF recommends genetic counseling and, if desired, BRCA testing after the age of consent 18 years .The American College of Physicians ACP examined the current medical research on routine pelvic exams and concluded there is limited benefit to routine annual exams for asymptomatic, non pregnant women.In 2012, a co-screening blood test for the human papilloma virus itself, the cause of nearly 90% of cases of cervical cancer, was incorporated into the guidelines.The bone density test is an x-ray, typically of your hip and spine.
We are thrilled that the FDA has cleared the Cerêve Sleep System for treating people with insomnia, states Eric Nofzinger, M.D., a board-certified sleep physician and the company s founder.Results from polysomnographic sleep measurements of subjects in sleep labs the gold standard for evaluating sleep showed a statistically significant reduction in latency to Stage 1 sleep, the time it takes to get into the first stage of sleep, as well as latency to Stage 2 sleep.With seven issued and nineteen pending patents, the Cerêve System is comprised of a software- controlled bedside device that cools and pumps fluid to a forehead pad that is worn through the night.We are working hard to bring our new technology to market to relieve the suffering experienced by those with chronic insomnia, states Craig Reynolds, President and Chief Executive Officer.The importance of sleep as a vital pillar of health along with diet and exercise is ever increasing, and current therapeutic options available to physicians and insomnia patients are limited.Wickwire, Shaya and Sharf: Health economics of insomnia treatments: The return on investment for a good night s sleep Sleep Medicine Reviews, Volume 30, December 2016, Pages 72-82 Chong Y, Fryar CD, Gu Q.
Figure1, which started out as a photo-sharing app for medical professionals, has quietly added direct messaging to its platform, showing signs the startup wants to be more of a Facebook and less of an Instagram in its field.Toronto and New York-based Figure1 only allows full access to its platform to users who are verified medical professionals or students including: doctors, nurses, dentists, physicians assistants, x-ray and lab technicians, pharmacists, medical students or residents.And on average 10,000 unique users check in to use Figure1 every hour according to co-founder and CEO Gregory Levey.Users typically share images of challenging or classic cases, and often seek help from the Figure1 community about how to treat patients, or even diagnose them.Patients personal information is not disclosed on the app, and Figure1 automatically blocks out faces, and then provides additional tools to help users blur personally identifiable traits such as a tattoos, from a photo before sharing.Levey said Figure1 also plans to deliver new services to its users through direct messaging including: in-app customer support kind of a no-brainer and a more creative mentorship program.
New data released Saturday at the American Society of Clinical Oncology annual conference in Chicago took a look at how liquid biopsies could influence how we treat cancer.These tests rely on something called "circulating tumor DNA", or the bits of DNA that are released from dying tumor cells into the bloodstream.Knowing what abnormalities a specific tumor possesses could help link cancer patients to treatments that specifically target those mutations as a more effective way approach cancer treatment.But the study did show some limitations: liquid biopsies were only able to pick up circulating tumor DNA mutations in 83% of the samples."Indeed, Foundation Medicine, which has both solid tumor sequencing tests and now a liquid biopsy test offers a dual-approach.Foundation's president and chief operating officer Steve Kafka told Business Insider that tissue biopsies will still be the gold standard, but there is one key area where liquid biopsy could make a major impact."What's exciting about liquid biopsy is — and we think this is going to be an important part of the picture — we believe this will allow physicians to now offer genomic insight to a broader swath of patients for whom tissue is not available," Kafka said.For some patients, there's not enough tissue to get, or they might be too sick to go into a surgical procedure to get the tissue removed."In the latest version of the test is that for the major cancer types, like lung and liver cancers, and ovarian cancer, we're exceeding 90% detection rates in all of those cancer types," he told Business Insider.Eltoukhy thinks it's a matter of time before liquid biopsies are more commonly adopted, comparing the situation to the adoption of wireless phones, where at first it seemed like landlines would still be critical in certain situations, but now cord-cutting is perfectly acceptable.
When some of the first killer apps came out, like Google Maps, Shazam or Angry Birds, every brand decided they needed an app of their own.We are surrounded by a million black slabs of screens, each of which is a potential opportunity and channel to engage and drive participation.The fact is that single-channel thinking defines failure in marketing, because if I, as a consumer, don t engage in more than one method, I either wasn t marketed to at all, or the marketing I did get exposed to caused no reaction, no engagement.So it s not limited to just the ad or the creative or the message being consistent across these mediums, but it s about how well you as a brand marketer walk along with her through her journey.We can t forget that experiences are a human construct, mixing functional and emotional qualities at the same time.About The AuthorMayur Gupta is the Senior Vice President, Head of Digital at Healthgrades, the leading online resource for comprehensive information about physicians and hospitals.
Predictions are that heart disease and cancer will be eradicated within a decade and other technologies, such as 3D printing and artificial intelligence, will further extend longevity and improve the quality of life, too.His knowledge is encyclopedic; here are some highlights drawn from his speech as well as from his annual conference in San Diego I attended last fall:• He said that Fitbits and other wearables, that measure everything from sleep to daily steps, will become insideables or sensors, monitoring and transmitting health outcomes to computers or healthcare providers.This invention is critical to millions suffering from mental or neurological maladies who forget or overdose their meds.This year, a major diagnostic device — the Tricorder XPrize of $10 million — will be awarded to one of many teams that have been developing for years a handheld device that can diagnose more than a dozen major health issues non-invasively breath, saliva or skin better than five board-certified physicians.• Siri for medicine already exists and several apps coach, check in and help patients manage issues.• Another health aid increasingly will be robots, already used in hospitals for surgery, moving patients or food and drug deliveries.
Or, more precisely, it shows a complete lack of understanding for how healthcare works and how positive health outcomes are actually achieved.Again, I don t know of a single successful sports team that did not have a relatively decent coach, and a good coach cannot simply show up to one practice per season, snap his fingers and expect a team to be successful.One could say these businesses are trying to be Uber for healthcare because they focus on easy and convenient transactions — simply walk in or make a call, get in the queue and finish with a prescription.But these business will not actually improve our healthcare cost and poor health outcome problems because they focus on transactions and not relationships.Instead of trying to create the Uber of healthcare by implementing services that overlay some aspect of our existing dysfunctional healthcare system e.g.Doing so will open up incredible opportunities: 1 physicians will have the time and financial freedom to innovate and experiment with new, easy and convenient ways to create strong patient-physician relationships, 2 it will allow us as patients the ability to form strong relationships with our own doctors, on our terms and in ways that leverage the latest technology to conveniently fit in to our busy daily lives and 3 most importantly to Silicon Valley, it will open up the door to entrepreneurs to build new tools and technologies that will enhance patient-physician relationships, not undermine them.
Click to Open Overlay GalleryGetty ImagesTheranos promised customers blood tests that were cheap, painless, and hassle-free.In anticipation of ready access to this democratizing technology—which, reminder, seems to have been plagued with problems—the blood testing company teamed up with Walgreens to create personal wellness centers in some 40-odd pharmacies in Arizona and California.Some pundits here, and elsewhere have argued the slow, uncertain pace of medical innovation is fundamentally mismatched with startup culture s move-fast-and-break-things ethos.So step number one: any successful biotech needs to have an internal culture amenable to science—plodding, but sedulous.Do something called a pre-mortem, he says.An exercise like this will let you see any problems your employees see—lapsed lab protocols, shaky science, out of control spending.
With the Web brimming with such bum medical advice—alarming patients and irking doctors worldwide—Google is now rolling out new search tools to try to strip away the medical malarkey or at least shove it down deep in search results.In the next few days, the Internet giant will be adding in new digital cards that should pop up above common results when you search for terms like stomach ache and skin rash.The cards are said to contain accurate medical information about common ailments, created with the help of doctors from Harvard Medical School and the Mayo Clinic.For now, Google will be rolling out the symptom search cards only in the US in English on iOS and Android apps, plus in search results on mobile phones and tablets.The feature will later be added to desktop browsers and be made available in more languages.A lot of times, what people find scares the daylights out of them, Wanda Filer, a family physician and president of the American Academy of Family Physicians, who was not involved with the good project, told the Wall Street Journal.
The FDA approved a controversial weight-loss device this month that allows obese patients to literally pump food from their stomach, through a tube, out their belly, and into the toilet.The AspireAssist consists of a surgically implanted tube that runs from the stomach to a small nozzle outside of the skin, and a system to pump and refill the lost contents.After a meal, patients fill a small reservoir with water, plug the system into the nozzle, and turn a lever to pump up to 30 percent of the stomach s content into the toilet in about 10 minutes.The system then refills the stomach with water from the reservoir.Gutman has made it his mission to get 4,000 physicians to sue the FDA for their approval of the device.But it isn t a joke, and some physicians support the AspireAssist.
SACRAMENTO -- As a defensive strong safety on his high school football team, Aaron Rubin was no stranger to injury treatment.It would mandate providers consult an existing database of patient prescription histories before recommending addictive drugs.But they're hoping recent national attention to the issue will persuade legislators to support reforms.The crisis is so undeniable that people no longer can "stick their head in the sand," said Carmen Balber, executive director of Consumer Watchdog.Between 1999 and 2014, more than 165,000 people died nationwide from prescription opioid overdoses, according to the U.S. Centers for Disease Control and Prevention.High-profile deaths -- like that of musician Prince, who accidentally overdosed on the painkiller fentanyl in April -- have increased the spotlight on the issue.
HealthTap is on a mission to make access to health care information and resources easier for everyone, both individually and in the workplace.However, for those outside of the U.S., it can be pretty difficult for someone to find answers to medical problems they or their loved ones are having.This is why HealthTap has brought its service to Facebook Messenger in the form of a chatbot.With this chatbot, which the company demonstrated at VentureBeat s MobileBeat conference today, patients can quickly find out what they might be suffering from and how to treat it.If that s not sufficient, they can submit questions to more than 100,000 doctors in the U.S. or even get in contact by video or simply messaging them.HealthTap believes by bringing its resources to one of the internet s most popular messaging apps, it can improve people s lives via access to free health care information.The chatbot lets people easily access the company s library of knowledge, such as what to do if your baby has had a diaper rash for more than a week.The chatbot also allows people to submit questions.Questions are reviewed by any of the more than 100,000 physicians who participate in HealthTap, with most getting responses within a day.
GlaxoSmithKline Plc has started a rheumatoid arthritis study using Apple Inc. s ResearchKit, marking the first time a drugmaker has used the health system for the iPhone to conduct clinical research.Glaxo wants to record the mobility of 300 participants over three months and will also ask the patients to input both physical and emotional symptoms, such as pain and mood.The app Glaxo created from ResearchKit comes with a guided wrist exercise that uses the phone s sensors to record motion, giving the drugmaker a standardized measurement across all users.The company will use the results to help design better clinical trials.The success of the study could help determine the pharmaceutical industry s future appetite for using Apple s products to conduct research.Risks include that test subjects will tire of entering information into the app, and, given the iPhone s $399 starting price, the sample may be skewed toward wealthier demographics.By using ResearchKit, London-based Glaxo may be able to reduce research costs, which can stretch into the millions of dollars.Observational trials, such as this one, can take months or even years to recruit and enroll patients, said Rob DiCicco, head of Glaxo s clinical innovation and digital platforms group.Certainly you ve also taken out the site costs, and the costs of having nurses and physicians explaining the studies to them and recording information.
The Olympics are still a few weeks away, but researchers at Leiden University s Institute of Physics are already smashing world records — if not Olympic ones — with a new nuclear magnetic resonance NMR microscope.In an effort to capture 3D images in atomic resolution, PhD students Jelmer T. Wagenaar and Arthur de Haan created the device to be 1,000 times more sensitive than similar microscopes and function at temperatures nearing absolute zero.NMR is the principle behind MRI machines, which enable physicians to peer through our skin and examine our anatomy with minimal or no invasiveness.When a patient places her arm in an MRI machine, the machine s magnetic field causes the atoms nuclei to line up, while specific radio waves induce some of those nuclei to flip on their axes, until the radio signal is turned off and the nuclei return to their original state.The movement of these nuclei generates waves that depict the location of the atoms, allowing physicians to generate an image of the inside of the body.It is like taking a photo — when somebody moves very fast, the photo gets a bit blurry.
Some medical professionals spend their careers in a lab, bettering the world through their research, while others focus on being caring physicians towards their patients.Dr. Cascone is a cancer researcher whose nascent career already shows great promise.She still works directly with her patients, though, and considers her clinical responsibilities part of the foundation of her career.My research is supported by Lung Cancer Alliance through a Young Investigator Award and the T32 National Institutes of Health training grant.After graduating from medical school in Naples, Italy, I entered the school s oncology fellowship program.As my research experience was coming into focus, I sought opportunities to directly help patients as well.
Swimmers know how uncomfortable it is to get water up the nose but, for people with chronic nasal issues, water can be the least of their concerns.When someone suffers from nasal trouble such as severe infections or nosebleeds, rhinologists and resident physicians often need to stick a camera and long tube down the patient s nasal cavity to investigate the problem.Most patients are not used to having something in their nose, so they may be very nervous, said Dr. Jose Gurrola II, a rhinologist at the University of Virginia Health System, in a UVA news release.It can be completely unnerving for the patient and the resident.To make the task a bit more comfortable, Gurrola teamed up with an otolaryngology resident at UVA, Dr. Robert Reed, and the director of the Advance Manufacturing and Rapid Prototyping Lab at UVA, Dwight Dart, to create 3D-printed skulls for training purposes.The models allow students, residents, and doctors to see, feel, and understand dimensions of real human geometry, Dart said in the same news release, adding that 3D printing will revolutionize the medical practice in coming years.
The study relies on an iPhone app to collect data about arthritic symptoms from users as they go about their daily lives.Launched last year, ResearchKit is designed to make it easier for medical researchers to access data about millions of potential subjects.So far there are just a handful of ResearchKit apps tied to clinical studies, but the GSK partnership is the first time Apple has joined forces with a major drug company.The Patient Rheumatoid Arthritis Data from the Real World PARADE study will use its app to track the mobility of over 300 participants suffering from rheumatoid arthritis, including information on their level of joint pain, fatigue, and changing moods.Certainly you ve also taken out the site costs, and the costs of having nurses and physicians explaining the studies to them and recording information, Rob DiCicco, head of Glaxo s clinical innovation and digital platforms group, told Bloomberg News.And collected data is typically anonymized by companies like Sage Bionetwork, removing any possible identifiable information before sending the data to the institution conducting the study.